LianBio Reports Voluntarily Delisting From Nasdaq;

2/28/24 7:13:06 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $LIAN alert in real time by email

LianBio expects to file a Form 25 with the SEC and Nasdaq relating to the voluntary delisting of its ADSs on or about March 11, 2024. As previously announced, the Company has initiated the wind down of its operations, including the voluntary delisting and deregistration of the company's ordinary shares and ADSs, following the completion of a comprehensive strategic review of the Company by the Board.

Get the next $LIAN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$LIAN

Date	Price Target	Rating	Analyst
1/3/2024	$5.00 → $3.00	Buy → Underperform	BofA Securities
12/22/2023	$7.00 → $4.00	Buy → Hold	Jefferies

More analyst ratings

$LIAN
Press Releases

Fastest customizable press release news feed in the world

LianBio Announces Voluntarily Delisting from Nasdaq
SHANGHAI, China and PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN) ("LianBio" or the "Company"), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that it has provided notification to The Nasdaq Stock Market, Inc. ("Nasdaq") of its intent to delist the Company's American Depositary Shares ("ADSs"), each representing the right to receive one ordinary share of the Company, from the Nasdaq Global Market. LianBio expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the voluntary delisting of its
2/28/24 7:00:00 AM ET
$LIAN
Biotechnology: Pharmaceutical Preparations
Health Care
LianBio Announces Completion of Strategic Review
SHANGHAI, China and PRINCETON, N.J., Feb. 13, 2024 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN) ("LianBio" or the "Company"), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that the Company's Board of Directors (the "Board") had completed its comprehensive strategic review of the Company and determined to initiate the wind down of its operations, including the sale of remaining pipeline assets, the delisting of its American Depositary Shares ("ADSs"), each representing the right to receive one ordinary share, from the Nasdaq Global Market ("Nasdaq") and deregistration under Section 12(b) of the Securities
2/13/24 7:00:00 AM ET
$LIAN
Biotechnology: Pharmaceutical Preparations
Health Care
LianBio Announces Departure of Chief Financial Officer
SHANGHAI, China and PRINCETON, N.J., Dec. 20, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that Yi Larson, Chief Financial Officer, has resigned from LianBio to pursue other opportunities, effective December 19, 2023. In connection with her departure, the LianBio Board of Directors has appointed Ehong (Maggie) Gu, current VP, Head of Global Finance, as Interim Chief Financial Officer. "We are grateful to Yi for her many contributions to strategic initiatives at LianBio and wish her continued success in her next role," said Konstantin Poukalov, Executiv
12/20/23 8:00:00 AM ET
$LIAN
Biotechnology: Pharmaceutical Preparations
Health Care

What's Going On With LianBio (LIAN) Stock?
LianBio – ADR (NASDAQ:LIAN) shares are trading higher by some 84% to $0.35 Friday afternoon on continued volatility. The company in late February announced its intent to delist its American Depositary Shares (ADSs) from the Nasdaq Global Market. This decision, made following a strategic review by the Board of Directors, involves winding down operations and deregistering its ordinary shares and ADSs. The company aims to reduce costs associated with regulatory compliance and management time, while returning value to shareholders through asset sales, out-licensing efforts, and dividends. Trading of ADSs post-delisting is expected to shift to privately negotiated sales and potentially an ove
3/15/24 3:44:38 PM ET
$LIAN
Biotechnology: Pharmaceutical Preparations
Health Care
LianBio Reports Voluntarily Delisting From Nasdaq;
LianBio expects to file a Form 25 with the SEC and Nasdaq relating to the voluntary delisting of its ADSs on or about March 11, 2024. As previously announced, the Company has initiated the wind down of its operations, including the voluntary delisting and deregistration of the company's ordinary shares and ADSs, following the completion of a comprehensive strategic review of the Company by the Board.
2/28/24 7:13:06 AM ET
$LIAN
Biotechnology: Pharmaceutical Preparations
Health Care
Why IPG Photonics Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of IPG Photonics Corporation (NASDAQ:IPGP) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued soft first-quarter guidance. IPG Photonics posted GAAP earnings of 89 cents per share, versus market estimates of 95 cents per share. The company’s quarterly sales came in at $298.90 million versus expectations of $286.12 million. IPG Photonics shares dipped 11.2% to $92.06 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers Ohmyhome Limited (NASDAQ:OMH) shares climbed 300% to $4.80. BioNexus Gene Lab Corp. (NASDAQ:BGLC) got a boost, surging 270% to $1.52. Digital Brands Group, Inc. (NASD
2/13/24 1:13:36 PM ET
$ALT
$ANET
$ARBB
$ARM
Biotechnology: Pharmaceutical Preparations
Health Care
Computer Communications Equipment
Telecommunications

LianBio Announces Voluntarily Delisting from Nasdaq
SHANGHAI, China and PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN) ("LianBio" or the "Company"), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that it has provided notification to The Nasdaq Stock Market, Inc. ("Nasdaq") of its intent to delist the Company's American Depositary Shares ("ADSs"), each representing the right to receive one ordinary share of the Company, from the Nasdaq Global Market. LianBio expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the voluntary delisting of its
2/28/24 7:00:00 AM ET
$LIAN
Biotechnology: Pharmaceutical Preparations
Health Care
LianBio Announces Completion of Strategic Review
SHANGHAI, China and PRINCETON, N.J., Feb. 13, 2024 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN) ("LianBio" or the "Company"), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that the Company's Board of Directors (the "Board") had completed its comprehensive strategic review of the Company and determined to initiate the wind down of its operations, including the sale of remaining pipeline assets, the delisting of its American Depositary Shares ("ADSs"), each representing the right to receive one ordinary share, from the Nasdaq Global Market ("Nasdaq") and deregistration under Section 12(b) of the Securities
2/13/24 7:00:00 AM ET
$LIAN
Biotechnology: Pharmaceutical Preparations
Health Care
LianBio Announces Positive Topline Results from Phase 3 EXPLORER-CN Trial Evaluating Mavacamten in Chinese Patients
• Mavacamten met the primary endpoint for the treatment of Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy • Mavacamten demonstrated a safety profile consistent with previous studies • If approved, mavacamten is expected to be the first cardiac myosin inhibitor approved in China for the treatment of oHCM • LianBio to host a live virtual analyst and investor event to review EXPLORER-CN topline data and the China market opportunity for mavacamten on Monday, May 1 at 8:00 a.m. EDT / 8:00 p.m. CST SHANGHAI, China and PRINCETON, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to pati
4/26/23 8:00:00 AM ET
$LIAN
Biotechnology: Pharmaceutical Preparations
Health Care

LianBio Reports Voluntarily Delisting From Nasdaq;

Chat with this insight

Recent Analyst Ratings for
$LIAN

$LIAN
Press Releases

Fastest customizable press release news feed in the world

LianBio Announces Voluntarily Delisting from Nasdaq

LianBio Announces Completion of Strategic Review

LianBio Announces Departure of Chief Financial Officer

$LIAN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

LianBio downgraded by BofA Securities with a new price target

LianBio downgraded by Jefferies with a new price target

$LIAN
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Gu Ehong sold $7,513 worth of Ordinary Shares (1,731 units at $4.34) and returned $5,724 worth of Ordinary Shares to the company (17,889 units at $0.32), closing all direct ownership in the company (SEC Form 4)

Poukalov Konstantin exercised 36,300 units of Ordinary Shares at a strike of $2.52 and covered exercise/tax liability with 19,218 units of Ordinary Shares (SEC Form 4)

Perceptive Advisors Llc exercised 72,600 units of Ordinary Shares at a strike of $2.52 and covered exercise/tax liability with 38,436 units of Ordinary Shares (SEC Form 4)

$LIAN
Leadership Updates

Live Leadership Updates

LianBio Appoints Wei Wei Chen to Board of Directors

$LIAN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D/A filed by LianBio (Amendment)

SEC Form SC 13D filed by LianBio

SEC Form SC 13G filed by LianBio

$LIAN
Market Insights

Live Market Insights

$LIAN
Financials

Live finance-specific insights

What's Going On With LianBio (LIAN) Stock?